AptarGroup reported first-quarter 2026 sales of $982.9 million, up 11% from $887.3 million a year earlier, even as core sales were flat.
Net income fell 8% to $73 million, and earnings per share slipped to $1.12 from $1.17. Adjusted earnings per share declined to $1.19 from $1.30, an 8% drop on a constant-currency basis.
Adjusted EBITDA margin narrowed to 19.2% from 20.7%, a decline of 150 basis points.
By segment, pharma sales rose 7%, with currency adding 7 percentage points, while core sales fell 1%. Within pharma, prescription dispensing systems sales dropped 10% as emergency medicine destocking weighed on results. Consumer healthcare sales increased 4%, injectables sales jumped 20%, and active material science solutions declined 1%.
Beauty sales climbed 19%, helped by a 9% currency benefit and a 7% contribution from acquisitions; core sales rose 3%. Closures sales increased 5%, with core sales flat.
Segment margins moved lower across the board. Pharma adjusted EBITDA margin was 33.3%, down 150 basis points. Beauty margin was 11.1%, down 100 basis points. Closures margin was 13.1%, down 270 basis points.
Aptar returned $131 million to shareholders in the quarter, including $100 million spent to repurchase 707,000 shares. The company also declared a quarterly dividend of $0.48 per share.
For the second quarter, Aptar said it expects adjusted EPS of $1.32 to $1.40. Today the company's shares have moved -0.69% to a price of $124.08. Check out the company's full 8-K submission here.
